Patient’s Corner: Living with Chronic Illness Vol. 2

By Dorothy Leone-Glasser

I met Mapillar Dahn and the MTS Sickle Cell Foundation, Inc. at our Rx in Reach GA Coalition Capitol Day. She was excited to participate in our event and had a table set to distribute Sickle Cell Awareness material and to engage visitors, attendees and legislators on the challenges of living with and caring for patients with this illness. She is guiding others to participate in understanding and conquering Sickle Cell Disease. I wanted you to know Mapillar and her journey as she continues her crusade to dispel the myths and ignorance surrounding the devasting sickle cell disease. 

Mapillar Dahn founded MTS Sickle Cell Foundation, Inc., a non-profit organization, to bring awareness to sickle cell disease and provide support to families affected by Sickle Cell Disease (SCD). Since its inception in November of 2015, the foundation has implemented many initiatives to assist sickle cell families giving them a community of healing and hope. MTS Foundation has sponsored over 100 children attending week-long summer camp, organizing health fairs, helping families avoid eviction and disconnection of vital utilities while conducting outreach visits to hospitalized sickle cell patients. The MTS Foundation works to spread sickle cell awareness and support clinical trials reaching over 20 million people in the United States and Canada.

SCD is an incredibly complex genetic blood disorder that impacts 100,000 Americans and millions more around the world. Because it is a blood disease, it’s complications can be felt anywhere blood flows in the body. A person can go blind from it, have a stroke, have organ damage, experience excruciatingly painful episodes called crises, and even die from its complications. Sickle Cell is an invisible disease that many outside of the SCD community, simply do not understand. This misunderstanding and a general lack of education around SCD has caused many myths and misconceptions about the disease to fester and cause systemically toxic and stigmatizing beliefs.

Mapillar Dhan is personally inspired to fight for those affected by sickle cell because she is the mother of three (3) beautiful daughters who all battle Sickle Cell Disease. She knows firsthand what people don’t know about living with this challenging disease and caring for children who struggle with its symptoms daily.  She is compelled to speak out loud and share a few points to keep in mind when engaging with SCD patients. She believes; the more you know, the more you can crush the barriers to care so patients can be assured they will receive the timely and appropriate treatment that they deserve. 

Here are some of her ‘Tips”:

  • RESPECT THE EXPERTISE OF THE PATIENT:  More needs to be done to build communication, sensitivity and awareness with SCD patients. Patients are experts in their own disease. SCD patients are not seen as partners in their own care. If a patient says, “This drug doesn’t work for me, but that one does,” what the doctor hears is, “This person has a drug of choice”. What is true is the SCD patient has lived with their disease since birth and knows what works for them.
  • SICK PEOPLE DO NOT ALWAYS LOOK SICK:  Please do not tell a SCD patient that he or she does not look sick. It is incredibly offensive and very hurtful. This is a community that has real issues with being taken seriously, especially in the hospital setting. SCD patients all around this country are being made to feel like they are faking their pain by medical professionals. They are being told that they are drug seekers simply because you can’t see their pain. SCD impacts every aspect of a person’s life and is extremely debilitating. Even when you do not see the severity of their illness; that does not mean that they are not experiencing a great deal of pain or feel very sick.
  • IT’S OK TO SAY YOU DON’T KNOW:  I wish more medical professionals would say that they do not know about how to treat SCD patients instead of minimizing their pain, rushing their care, and prematurely sending them home, only for them to return to the hospital oftentimes in an even much critical condition than before. When it comes to treating SCD complications, time does matter
  • THE DISEASE AFFECTS EVERYONE DIFFERENTLY:  
    My daughters are three sisters with the same mother and father all battling the same disease. They all have different symptoms and different experiences.

My oldest daughter, Tully, who is now 17, started to have severe bouts of pain, known as pain crises, when she was 6 months old. Until a year ago, she was having two to three crises a year, which means she was hospitalized for at least a week. About a year ago, after a blood transfusion, she developed antibodies to the blood group antigen, Jsb, which means she can only get transfusions from the 1-2% of donors who lack this antigen.
My other daughters have not had pain crises, but my middle daughter, Khadeejah, who is 15, had a stroke when she was 7 years old. Since then, she’s had monthly blood transfusions and 10 surgeries, including a major brain surgery.
My youngest daughter, Hajar, who is 11, struggles with the disease in her own way. She doesn’t have obvious symptoms or require regular blood transfusions, but she has cognitive challenges that are the result of “silent” mini-strokes associated with SCD.

“We have to look at individual patients and treat the disease more broadly. As a community, we know that not much is taught about sickle cell disease in medical and nursing schools. Until we can work to change that, a healthy dose of vulnerability, understanding, compassion, care, and empathy needs to be prescribed when treating people with SCD.”

To learn more about MTS Sickle Cell Foundation click  here.

Mapillar Dahn headshot
Mapillar Dahn
Founder & CEO,
MTS Sickle Cell Foundation
Dorothy Leone Glasser headshot
Dorothy Leon Glasser
Executive Director, Advocates for Responsible Care
Co-Chair, Georgia Bio Patient Advocacy Alliance
June 15, 2026
The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.
June 10, 2026
In recent comments to the Department of Justice (DOJ) and Federal Trade Commission (FTC), PULSE highlighted critical reforms to ensure that U.S. competition policies support – and do not impede – the pro-competitive mergers and acquisitions (M&A) and other collaborations that drive American life sciences innovation. PULSE submitted comments in response to two joint DOJ/FTC Requests related to Guidance on Collaborations Among Competitors and Improvements to the Premerger Notification and Report Form (HSR Form). Read below for key takeaways from PULSE’s comment letters: 1. Life Sciences Innovation Depends on Collaboration “At its core, life sciences innovation is overwhelmingly collaborative. The cutting-edge medicines and cures developed by America’s life sciences industry are rarely the result of just one sole actor. Instead, they more often emerge from a calibrated sequence of partnerships… that collectively usher a biomedical breakthrough from early-stage discovery to FDA approval and delivery to patients.” – PULSE, Comments on Guidance on Collaborations Among Competitors 2. Policies that Ignore the Fundamental Role of Life Sciences M&A Risk Chilling Innovation for Patients “Against the significant challenges and pressures inherent to life sciences innovation, such policies that needlessly delay pro-competitive transactions have significant ripple effects: eroded investment incentives, disruptions in the path to launch and, ultimately, slowed or stalled development of new treatments and cures for patients.” – PULSE, Comments on Improvements to the HSR Form 3. Clear, Predictable Standards Can Support Competition and Innovation in America’s Life Sciences Ecosystem “Preserving clear and workable pathways for collaboration is therefore essential to sustain the broader ecosystem that delivers innovation and sustains America’s status as the world leader in life sciences innovation.” – PULSE, Comments on Guidance on Collaborations Among Competitors Leading business and industry organizations echoed and reinforced these priorities. Their comments highlight the unique market dynamics of life sciences innovation and the importance of collaboration and M&A – particularly with respect to early-stage R&D. “Because drug development typically takes over a decade, and the vast majority of drugs in development never make it to market, the antitrust risks associated with R&D collaborations in this space may be less than with other R&D collaborations.” – ABA Antitrust Law Section, Comments on Guidance on Collaborations Among Competitors “In the biopharmaceutical sector, for instance, R&D ventures in the pre-clinical or Phase I stages should be presumed lawful. At these early stages, about 90% of drugs never make it to market, so these collaborations are far too distant from commercialization to pose a meaningful threat to competition.” – U.S. Chamber of Commerce, Comments on Guidance for Collaborations Among Competitors “Healthy M&A activity also aids company formation and capital raising earlier in a business’s life cycle, as entrepreneurs and early-stage investors often depend on M&A for an exit opportunity. Conversely, discouraging business combinations by imposing burdensome one-size-fits-all standards on all transactions, like those imposed by the 2024 amendments, would disincentivize early-stage innovation and slow down economic growth.” – National Association of Manufacturers, Comments on Improvements to the HSR Form The bottom line: A balanced approach to antitrust enforcement policy should support life sciences M&A and other collaborations, ensuring new medicines continue to reach patients, while preserving a diverse and collaborative ecosystem. PULSE urges the agencies to adopt clear, workable and predictable standards that companies can apply with confidence. That includes preserving enforcement safety zones for low-risk, pro-competitive collaborations, as well as ensuring the HSR Form facilitates a timely, focused and fit-for-purpose screening process for life sciences M&A deals. Click below to read PULSE’s full comments: PULSE Comments on Guidelines on Collaborations Among Competitors PULSE Comments on Improvements to the HSR Form Source: PULSE Urges FTC, DOJ to Support Pro-Competitive Life Sciences Collaborations and M&A - Partnership for the U.S. Life Science Ecosystem (PULSE)
June 5, 2026
 June 5, 2026 - Georgia Life Sciences is pleased to announce the promotion of Stacey Bowlin to Executive Vice President . Since joining Georgia Life Sciences in 2024, Stacey has played a central role in advancing the organization’s strategic visibility, industry partnerships, membership growth, and statewide engagement. Her leadership has helped strengthen Georgia Life Sciences’ position as a leading voice for Georgia’s biotechnology, pharmaceutical, medical device, diagnostics, and digital health sectors. “Stacey has made an extraordinary impact on Georgia Life Sciences in a very short period of time,” said Maria Thacker Goethe, President & CEO of Georgia Life Sciences . “She successfully led our transformation from Georgia Bio to Georgia Life Sciences, helping modernize our brand and better reflect the full breadth of Georgia’s life sciences industry. She has also strengthened our member recruitment and retention strategy, deepened engagement across the ecosystem, and brought a level of operational discipline that has helped position the organization for continued growth. I am thrilled to recognize Stacey’s leadership and contributions with this well-deserved promotion to Executive Vice President.” In her expanded role, Stacey will continue to lead key areas of organizational strategy, operational execution, member engagement, and long-term growth. She will work closely with the CEO to support financial and organizational performance, oversee key initiatives, and help translate Georgia Life Sciences’ long-term vision into actionable strategies that strengthen the state’s life sciences ecosystem. With more than two decades of experience in strategic engagement, marketing, operations, and industry development, Stacey brings a collaborative, mission-driven approach to leadership that aligns closely with Georgia Life Sciences’ vision for the future.
MORE POSTS